The calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) plays a central role in many cell signaling pathways. CAMKK2 activates CAMK1, CAMK4, AMPK, and AKT leading to numerous physiological responses. Deregulation of CAMKK2 is linked to several diseases, suggesting utility of CAMKK2 inhibitors for oncological, metabolic and inflammatory indications. In this work we review the role of CAMKK2 in biology and disease. Through analysis of literature and public databases we have identified starting points for CAMKK2 inhibitor medicinal chemistry campaigns. These starting points provide an opportunity for the development of selective CAMKK2 inhibitors and will lead to tools that delineate the roles of this kinase in disease biology.
: A) Superimposed structures of CAMKK1 (yellow, PDB 6CD6) and CAMKK2 (green, PDB 6BKU) bound to GSK650394. STO-609 (as bound to CAMKK2, PDB 2ZV2) is also shown in magenta. Spheres show positions where residues differ within the ATP-binding site of the two CAMKKs. B) Inset shows a top view of the ATP-binding sites of both CAMKKs.
The ATP-binding pockets of CAMKK1 and 2 have differences in residues that could also be exploited (Figure 2) . Residues Leu233, Arg234 and Lys235 in CAMKK1 are replaced with Val270, Asn271 and Gln272 in CAMKK2. These changes cause the backbone to adopt a different conformation, primarily through the Leu233 in CAMKK1, which is larger than the equivalent Val270 in CAMKK2. Although challenging, the differences in residues/conformations in the hinge region could potentially be used to design selective inhibitors. [58] 
CAMKK2 as a potential drug discovery target
In light of CAMKK2's important role in several signaling pathways, it is no surprise aberrant activation can lead to improper biological functions. Inappropriate activation or overexpression of CAMKK2 has been implicated as a key driver in prostate, breast, ovarian, gastric and hepatic cancers. [62] [63] [64] [65] [66] [67] [68] [69] [70] Decreasing CAMKK2 activity using pharmacological inhibition or depletion of CAMKK2 using small interfering RNA (siRNA) reduces cell proliferation, migration and invasion in several cancer types. [68, [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] The link between cancer and CAMKK2 is well documented in prostate cancer. In prostate cancer, the androgen receptor (AR)-signaling pathway is key in regulating disease progression, and is a major target for therapeutic intervention. [82, 83] Inhibition of the androgen receptor and reduction of circulating androgens have been the primary approaches used to treat the disease, but the therapies often succumb to drug resistance. CAMKK2 is upregulated in prostate cancer directly through the androgen receptor. [71, 78, 84] In cancer cell lines, CAMKK2 activates AMPK, altering cell metabolism and promoting cell proliferation. [78] There are seemingly conflicting reports on the role of CAMKK2 in LNCaP prostate cancer cell lines, indicating that further studies are required. [80, 84] . In spite of this, both downregulation with siRNA and pharmacological inhibition of CAMKK2 with the inhibitor STO-609 have been shown to reduce cell proliferation, migration, and invasion. [71, 78, 80, 84, 85] Obesity, aberrant metabolism and type 2 diabetes are causative factors in non-alcoholic fatty liver disease (NAFLD), which is linked with rising incidence of hepatocellular carcinoma (HCC). [86, 87] CAMKK2 activation of hypothalamic AMPK stimulates ghrelin signaling, and promotes the desire to eat. [88] CAMKK2 inhibition has been shown to limit ghrelin-induced food intake in mice. [89] Furthermore, CAMKK2 null mice accumulate less body weight than wild-type mice when fed a high-fat diet, thereby offering protection against diet-induced obesity that promotes NAFLD. [90] In mouse models, treatment with STO-609 improved hepatic steatosis (fatty liver disease) compared to control groups. [91] CAMKK2 expression is significantly upregulated in HCC and correlates negatively with patient survival. [92] In several HCC cell lines, depletion of CAMKK2 using siRNA or inhibition of the enzyme with STO-609 decreased proliferation. [92] These studies suggest that CAMKK2 inhibition may be useful for the direct treatment of HCC, and also prevention of NAFLD, which is a risk factor for HCC.
In gastric cancer, studies using siRNA for knockdown and STO-609 for inhibition demonstrated decreased proliferation in various cell lines. [81, 93] Increased apoptosis was found in SNU-1 and N87 cancer cells, but not in normal gastric epithelial cells. [93] Increased expression of CAMKK2 in glioma correlates with negative outcome. Reducing CAMKK2 protein levels using siRNA leads to reduced proliferation, migration and invasion. [76] Similar results have been found in ovarian and breast cancer. Inhibition using STO-609 or siRNA leads to decreased proliferation and apoptosis in ovarian cancer cell lines, and to cell cycle arrest in the G1 phase in breast cancer cell lines. [68, 79] A recent publication demonstrated that CAMKK2 plays a key role in regulation of the immune-suppressive microenvironment in breast cancer. [94] CAMKK2 knockout mice had attenuated growth of grafted mammary tumors, which the authors attribute to a reduction in immunosuppressive activities. This phenotypic outcome was replicated using pharmacological inhibition with two chemically distinct CAMKK2 inhibitors. [95] A dominant negative CAMKK2 mutant showed reduced cell migration in DAOY medulloblastoma cell lines. [96] This study also investigated the effect of inhibition with STO-609 on migration, demonstrating reduced DAOY cell migration in a scratch assay. [96] The potential therapeutic value of CAMKK2 inhibitors is not limited to the field of oncology. Due to the multitude of signaling pathways impacted by CAMKK2, and its role in whole-body energy homeostasis, this is of no surprise. Increasing evidence supports CAMKK2 inhibition as an avenue for the treatment of skeletal diseases. Osteoblasts (OBs) and osteoclasts (OCs) are key cells in bone tissue maintenance. [97] CAMKK2 is expressed in both OBs and OCs, and its inhibition increases osteoblast differentiation and bone growth, while suppressing osteoclast differentiation. [98] A subsequent study by the same authors provides evidence that CAMKK2 inhibition by STO-609 stimulated bone growth and reversed age-associated decline in bone strength, volume and several other parameters that are indicators of bone health. [99] 
STO-609
The plethora of evidence discussed above indicates the promise of pharmacological intervention with CAMKK2 inhibitors. In the literature, pharmacological inhibition of CAMKK2 almost exclusively relies on the use of STO-609. [68, 71, 78, 93, [100] [101] [102] Although widely used, there is opportunity for improvement of this molecule. STO-609 is described as a selective inhibitor of the CAMKKs without significant activity on the other CaMKs. STO-609 is a potent inhibitor of CAMKK2 and has a five-fold lower Ki for CAMKK2 than CAMKK1. [103] A recent publication by York et al. characterized the metabolism, toxicity, pharmacokinetics, distribution and efficacy of STO-609. [104] Results in this paper demonstrate that STO-609 is well tolerated in mice without significant hepatic or renal toxicity. Exposure to human liver microsomes (HLM) and subsequent mass spectrometry analysis showed that STO-609 was metabolized to three mono-hydroxylated byproducts, principally by CYP1A2. In mice dosed intraperitoneally, the plasma half-life (t1/2) of STO-609 was between 8-12 hours. STO-609 was found in tissues that express CAMKK2, although low concentrations were found in skeletal muscle and brain. [103] The latter result is not unexpected as the physicochemical properties of STO-609 make it unlikely to cross the blood-brain barrier.
Although STO-609 has been widely used as a pharmacological inhibitor of CAMKK2 in the literature, it is not an ideal molecule, in part due to its poor aqueous solubility. STO-609 is a polycyclic aromatic compound containing five fused rings, and analysis of medicinal chemistry data sets suggests this is a liability. [105, 106] The extended planar ring system allows for significant p-p stacking, which leads to more stable crystal lattices, and contributes to poor solubility. Compounding this issue is the presence of the carboxylic acid moiety that also contributes to high crystal lattice energy via strong H-bond interactions. STO-609 is usually solubilized in DMSO or NaOH solution, which at higher doses can complicate use of the compound and lead to aberrant results. Indeed, a 10% DMSO solution is often used to kill cells in vitro, and as little as 0.25% DMSO can have inhibitory effects on some cell lines. [107] There are no published reports describing structure activity relationships for STO-609, or attempts to improve its properties. The available crystal structures of STO-609 bound to CAMKK2 could be used in attempts to improve STO-609 by adding solubilizing groups, increasing sp 3 character, and decreasing the number of rings.
Another critical issue with STO-609 is its selectivity across the kinome. In the literature it is frequently described as being selective for CAMKK2. However careful examination revealed that STO-609 inhibits seven kinases with a similar potency to CaMKK1 (MNK1, CK2, AMPK, PIM2, PIM3, DYRK2, DYRK3). [108] Bain et al also found that at 1 µM, STO-609 was a more effective inhibitor of PIM3 than CAMKK2 and identified ERK8 as a collateral target. Further evidence to support these kinases as collateral targets of STO-609 is found in the MRC PPU (Medical Research Council Protein Phosphorylation Unit Dundee, UK) screening database where MNK1, PIM3, and ERK8 were inhibited by STO-609 at 1 µM.
Inhibitors having off-target activities can confound the mechanistic interpretation of phenotypic data, especially when the inhibitor in question is utilized at high concentrations in cellular or in vivo assays, which is frequently the case with STO-609. For example, the proto-oncogene PIM3 is a kinase that can prevent apoptosis and promote cellular survival, leading to tumorigenesis. [109] PIM3 has been implicated in hepatic, pancreatic, colon and gastric cancers. [110] [111] [112] [113] The upregulation of CAMKK2 and PIM3 in HCC, and the fact that both are inhibited by STO-609, suggests that the results of some may not be solely due to CAMKK2 inhibition. It has also been shown that STO-609 binds and activates the aryl hydrocarbon receptor which could in some contexts be confounding due to induction of P450s or regulation of immune response. [114] The poor drug-like properties of STO-609 that require the use of high concentrations and non-ideal formulations coupled with its kinase off-target interactions underscore the need for a more selective inhibitor with better physiochemical properties that can be used to more accurately probe the functions of CAMKK2 in cells and in vivo.
Results

STO-609 -Selectivity
To further investigate the kinase selectivity profile of STO-609, it was screened across a panel of over 400 wild-type human kinases (KINOMEscanâ, DiscoverX). At 1 µM STO-609 was revealed to be a potent inhibitor of 13 kinases in addition to CAMKK2. The most potently inhibited kinases were CDKL2, GRK3, STK36, CSNK2A2, YSK4 and DAPK2. The kinome treespot and PoC values are shown in Figures 3A and 3B. The full KINOMEscan data is available in the SI (Table S1 ). These single concentration screening results require follow-up experiments in both dose-response and orthogonal assays to validate activity. The KINOMEscan results corroborate PIM2 and PIM3 as targets of STO-609. Bain et al report casein kinase 2 (CK2) as being potently inhibited with an IC50 of 190 nM. [115] In the KINOMEscan data a truncated version of CK2, using only the catalytic subunit alpha2 (CSNK2A2), was also inhibited effectively following treatment with 1 µM of STO-609. CK2 is overexpressed in several cancers including breast, lung, prostate and kidney, and is associated with aggressive tumorigenesis. [116] [117] [118] [119] [120] Three potential off targets identified in the KINOMEscan, CDKL2, GRK3 and STK36, were not present in Bain et al's or MRC's profiling panels. CDKL2 and GRK3 have been implicated in breast cancer progression and their overexpression correlates with poor prognosis. [121, 122] STK36 is a node in the Hedgehog signaling pathway mediating GLI-dependent transcription. [123] These preliminary KINOMEscan results require confirmation in orthogonal kinase inhibition assays.
The evidence of significant off-target kinase inhibition by STO-609 is compelling. Given that several of the kinases that are potently inhibited are also potential oncology targets, caution must be used when assigning experimental results exclusively to CAMKK2 inhibition. High quality probes are essential for elucidating the role of kinase signaling in healthy and diseased biological systems and it is possible that inaccurate conclusions may be drawn from use of non-selective probes. [124, 125] Ideally, concurrent testing of a chemically distinct CAMKK2 inhibitor should be used as an orthogonal probe to verify the mechanism of action.
Other CAMKK2 tool compounds
In the literature there are two recent publications that described potential CAMKK2 tool compounds. In the publication by Price et al. the inhibitors disclosed were based on 3,5-diaryl-7-azaindoles (2), 3,6disubsituted-7-azaindoles (3), 2,4-diaryl-7-azaindoles (4) and 2-anilino-4-aryl-pyrimidine (5) A. B.
CAMKK2 activity but a co-crystal structure was disclosed. [126] Structures of these compounds and STO-609 are depicted in Figure 4 .
Figure 2:
The most cited CAMKK2 inhibitor STO-609 (1). The scaffolds of CAMKK2 inhibitors (2-6) with structure activity studies described in the literature. [89, 126] Price et al identified CAMKK2 inhibitors from a screen of 12,000 ATP-competitive kinase inhibitors and similar pharmacophores. The azaindole and anilino-pyrimidine cores are well documented as Type 1 kinase inhibitors that displace ATP from the hinge region of the enzymes. [127] Although significant effort was invested in each series, affording potent single digit nanomolar CAMKK2 inhibitors in biochemical assays, various factors such as poor cell permeability, low solubility, and poor in vivo absorption meant that most compounds were unsuitable for probing CAMKK2 activity in vivo. In addition, broad kinase screening data for the compounds was not available, so kinome-wide selectivity is unknown. The authors were successful in finding a central nervous system (CNS) penetrating compound. When orally dosed, rats treated with the compound showed a 40% reduction in ghrelin-induced food intake compared to a control group. [89] The 1,2,6-thiadiazin-4-one derivatives identified by Asquith et al. represent an unusual class of hinge binders. The compounds were screened against a kinase panel representing the major branches of the kinome. CAMKK2 hits were identified using a thermal shift assay. Analogues were synthesized based on the best compound from the initial screen yielding inhibitors with low micromolar CAMKK2 inhibitory activity. The co-crystallization of CAMKK2 with one of the inhibitors showed that the thiadiazinone carbonyl and one of the anilino NH groups interacted with the hinge region. [126] 
Literature survey of CAMKK2 inhibitor chemotypes
Given the modest selectivity of STO-609, and the lack of alternative high-quality tool compounds, a survey of the literature and several public databases was undertaken to identify alternative CAMKK2 inhibitor chemotypes. Candidate CAMKK2 inhibitors were acquired and their binding assessed in a DSF assay and CAMKK2 inhibition enzyme activity assay.
The databases mined in this study were the 'Kinase Profiling Inhibitor Database' provided by the University of Dundee, the 'Kinase Inhibitor Resource' provided by the Fox Chase Cancer Center and Reaction Biology Corporation, 'KInhibition' provided by Fred Hutchinson Cancer Research Center and the LINCS KINOMEscan database provided by Harvard Medical School. Using a selection criterion of >25%
inhibition at 1 µM, 25 compounds were identified. The inhibitors represent a diverse range of chemotypes including 2,4-dianilinopyrimidines, 2-anilino-4-arylpyrimidines, indolinones, pyrazolo-pyrimidines, fused pyrimidines, quinolines and bis-indoles. The set was supplemented with additional compounds that were described as CAMKK2 inhibitors in the literature, or where CAMKK2 had been noted as a collateral target during broad kinase screening activity. The set was further expanded to include commercially available analogues for some of the chemotypes, such as 2-anilinopyrimidines and oxindoles. A total of 52 compounds (Table S2) were evaluated against CAMKK1 and CAMKK2 in a DSF and enzyme inhibition assay.
Differential Scanning Fluorimetry & Enzymology
DSF is commonly employed to evaluate inhibitor binding and stabilization. [128, 129] The compounds ability to stabilize purified kinase domain of CAMKK1 and CAMKK2 was assessed. The results are presented in Table 1 and Figure 5 . Generally, the ΔTm values generated on CAMKK2 were higher compared to CAMKK1. This observation does not indicate that the compounds were more potent CAMKK2 inhibitors, but only that they induced a larger change to the melting temperature of the protein.
In CAMKK1 five staurosporine analogues induced the largest shifts with ΔTm >15 °C. Other very potent binders of CAMKK1 are the quinoline OTSSP167 and the azaindole GSK650394, which both shifted the melting temperature by >15 °C. GSK650394 induced the highest melting temperature shift in CAMKK2 (20.7 °C). The benzimidazoles crenolanib and CP-673451 and the quinoline OTSSP167 had the next highest CAMKK2 ΔTm values. Compounds were tested in a CAMKK2 enzyme inhibition assay at 0.01, 0.1 and 1 µM concentrations ( Table 1) . STO-609 resulted 21% activity remaining (PoC) at 1 µM and generated an IC50 of 56 nM when tested in a full 8-point dose response assay. At 1 µM ten compounds had lower PoC values than STO-609, representing a range of different chemotypes. IC50 values were generated for these compounds, and also for AZD3463, crenolanib and BI2536, three inhibitors which had been co-crystallized with CAMKK2. [130] The ten most potent CAMKK2 inhibitors are shown in Figure 6 . Their IC50 values correlated well with published values where available. [131] The IC50 for GSK650394 was 3 nM (pIC50 = 8.5), in line with the activity reported in the literature (pIC50 = 9.2) and was the most potent CAMKK2 inhibitor identified in this study. Kinase selectivity was calculated using publicly available data and these data are presented in Table 2 . For data from single concentration screening the number of kinases inhibited by greater than 90% (or PoC <10%) at the given screening concentration was divided by the number of kinases in the screening panel to generate an S10 selectivity value. If IC50 data was available, the selectivity metric was calculated by dividing the number of kinases with an IC50 below the chosen threshold by the number of kinases screened. Caution should be used in comparing these selectivity values, since data was collected using different assay formats, various inhibitor concentrations, and reported in different formats (for example PoC, Kd values, and IC50 values). However, the results in Table 2 do provide a useful qualitative assessment of kinase selectivity. 
Discussion
When profiled at MRC, at 1 µM GSK650394 inhibited 7 of 85 kinases by more than 90%, equating to an S10 value of 0.082. In a larger a panel of 334 kinases (Reaction Biology Corporation), GSK650394 inhibited 29 kinases by more than 90%, representing a nearly identical S10 value of 0.083 ( Table S3 ). The number of kinase off-targets limits the utility of GSK650394 as a chemical probe for CAMKK2, since attributing a phenotypic response to a single kinase would be precarious. The S10 metric could be calculated for STO-609, BI2536 and OTSSP167 at 1 µM, and for CDK 1/2 inhibitor III and JAK3 inhibitor VI, at 0.5 µM. STO-609 had moderate selectivity with an S10 at 1uM of 0.015. In this set, BI2536 appears to be the most selective of the CAMKK2 inhibitors. In the literature BI2536 was reported as a potent PLK1, PLK2 and PLK3 inhibitor, with Kd's <10 nM. [133] . In addition to the collateral PLK inhibition, BI2536 has been shown to be a potent inhibitor of BRD4, which is a critical regulator of cell division and confounds its use as a selective kinase inhibitor probe. [134] OTSSP167 is an extremely potent but promiscuous kinase inhibitor, with an S10 at 1 µM of 0.66. Neither CDK1/2 inhibitor III or JAK3 inhibitor VI can be considered selective, even at a lower concentration of 0.5 µM, they have S10 values of 0.278 and 0.163 respectively. The S10 metric could not be calculated for AP26113, but IC50 values were generated against a panel of 289 kinases. [135] From this panel, AP26113 generated IC50 values below 10 nM for 10 kinases, and below 50 nM for 24 kinases. Thus, it is likely to potently inhibit almost 10% of the kinome. Kinases inhibited by AP26113 included known oncology targets such as FER, EFGR and FLT3 and the polypharmacology of this compound may contribute to its efficacy in patients. ALK-IN-1 is an analogue of AP26113, differing only in the solvent exposed moiety. Although kinome profiling data was not available for ALK-IN-1, it may show polypharmacology similar to AP26113. Lestaurtinib was profiled in the KINOMEscan panel and was extremely promiscuous, demonstrating Kd's <20 nM for 111 out of 443 kinases. There was no profiling data available for CP673451 but the S10 value for crenolanib, a close analogue, was 0.142. Table 2 revealed several potential starting points for development of potent and selective CAMKK2 inhibitors. GSK650394 is potent but suffers from poor kinase selectivity. Several strategies could be utilized to increase the compound's kinase selectivity. Price et al demonstrated that replacement of the carboxylic acid group by an amide retained CAMKK2 potency. [89] The authors also demonstrate that the cyclopentyl group occupied a pocket that tolerated alternative substitutions, although no group larger than the cyclopentyl was reported. The unsubstituted phenyl ring could also be functionalized, and there is likely room to grow this into the solvent exposed region where kinases tend to be less highly conserved. A promising strategy would be bioisosteric replacement of the azaindole core, since it is known that the hydrogen bond interactions between a kinase inhibitor and the enzyme's hinge region are important for selectivity and potency. [136] BI2536 represents another potential starting point to develop a potent and selective CAMKK2 inhibitor as the number of off targets is limited. The activity of the compound on the PLK family could be addressed by modifying the core, specifically by further functionalizing the fused piperazinone ring. The N-methyl could be replaced with different alkyl groups, which may also be applied to the ethyl group. There is room to extend the compound at the ethyl and potentially install a group that can interact with the lysine that forms a H-bond with the acid moiety in GSK650394. The cyclopentyl group of BI2536 also occupies the same pocket as identified in GSK650394 and would be an interesting group to modify. [131] Modifications of these groups could induce selectivity for CAMKK2 over the PLKs. However, it will also be important to remove all the off-target bromodomain activity of this chemotype. Although we identified other potent scaffolds, their promiscuity is severe, and they do not represent good starting points for the development of selective inhibitors.
The data in
Conclusion:
CAMKK2 is an extremely important kinase in cell signaling, playing an essential role in key cellular processes. Deregulation of CAMKK2 has implications in oncological, metabolic and neurological diseases. There is currently no high quality CAMKK2 chemical probe available to the scientific community for use in target validation and pre-clinical translation studies. The need for a selective CAMKK2 inhibitor is acute, given that the most widely studied inhibitor, STO-609, has poor solubility and shows collateral inhibition of several other regulatory kinases. Through this review of the literature and public databases and generation of new screening data, additional starting points for the development of selective CAMKK2 inhibitors have been identified and strategies to optimize them have been proposed. We anticipate that these results will help the community make further progress towards CAMKK2 inhibitors that will delineate roles played by CAMKK2 in disease and can be used to explore its inhibition in a clinical setting.
Materials and Methods
CAMKK1 and CAMKK2 DSF assay
Small molecule screening by DSF were performed as described previously. [137, 138] Briefly the DSF assay was performed in 96-well format. Purified CAMKK1 or CAMKK2 was diluted to 2 µM kinase in 100 mM potassium phosphate pH 7.5, 150 mM NaCl, and 10% glycerol supplemented with 5x SYPRO Orange (Invitrogen). All assay experiments used 19.5 µL of 2 µM kinase and SYPRO Orange mixture. Compounds solubilized in DMSO were used at 12.5 µM final concentration, with a 2.5% concentration of DMSO per well. PCR plates were sealed using optically clear films and transferred to a C1000 thermal cycler with CFX-96 RT-PCR head (BioRad). The fluorescence intensity was measured over a temperature gradient from 25-95 °C at a constant rate of 0.05 °C/s. Curve fitting and protein melting temperatures were calculated based on a Boltzmann function fitting to experimental data (GraphPad Prism 8). Protein with the addition of 2.5% DMSO was used as a reference. All experiments were carried out in triplicate and the mean of the DTm is reported. Compounds that provided negative values are presented as having a ΔTm of 0 °C. CAMKK2 enzyme assay CAMKK2 activity was determined by measuring the transfer of radiolabeled phosphate from [γ-32 P]-ATP to a synthetic peptide substrate (CaMKKtide) as previously described. (38) Briefly, purified recombinant CAMKK2 (100 pM) was incubated in assay buffer (50 mM HEPES [pH 7.4], 1 mM DTT, 0.02% [v/v] Brij-35) containing 200 µM CaMKKtide (Genscript), 100 µM CaCl2, 1 µM CaM (Sigma-Aldrich), 200 µM [γ-32 P]-ATP (Perkin Elmer), 5 mM MgCl2 (Sigma-Aldrich) and various concentrations of inhibitors (0-1 µM) in a standard 30 µl assay for 10 min at 30 °C. Reactions were terminated by spotting 15 µl onto P81 phosphocellulose paper (GE Lifesciences) and washing extensively in 1% phosphoric acid (Sigma-Aldrich). Radioactivity was quantified by liquid scintillation counting.
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